SG11201807729YA - Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases - Google Patents

Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases

Info

Publication number
SG11201807729YA
SG11201807729YA SG11201807729YA SG11201807729YA SG11201807729YA SG 11201807729Y A SG11201807729Y A SG 11201807729YA SG 11201807729Y A SG11201807729Y A SG 11201807729YA SG 11201807729Y A SG11201807729Y A SG 11201807729YA SG 11201807729Y A SG11201807729Y A SG 11201807729YA
Authority
SG
Singapore
Prior art keywords
international
receptor
toll
peptides
tlr
Prior art date
Application number
SG11201807729YA
Inventor
Leung-Kei Siu
Feng-Yee Chang
Pele Choi-Sing Chong
Chih-Hsiang Leng
Original Assignee
Kemyth Biotech Co Ltd
Chong Pele Choi Sing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemyth Biotech Co Ltd, Chong Pele Choi Sing filed Critical Kemyth Biotech Co Ltd
Publication of SG11201807729YA publication Critical patent/SG11201807729YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M1111101110101011111 HO 11111 0111011101011101011101101111101111011# International Bureau 0.. .... .. ...... ... (10) International Publication Number (43) International Publication Date WO 2017/152270 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) (71) Applicant International C07K 14/315 A61K 35/74 (2015.01) A61K 38/16 (2006.01) A61P 3/10 (2006.01) International International Priority Data: 62/305,164 Applicant: KEMYTH BIOTECH No.306, Yuanpei St., Hsinchu Inventor; and #2101 44 St. (CA). Inventors: SIU, chu City, 30015 36, Section 6, (72) Patent Classification: (2006.01) Application Number: Filing Date: 8 March 11490 (TW). LENG, Chih-Hsiang; 35 Keyan Road, C07K 7/06 (2006.01) Zhunan Town, Miaoli County, 350 (TW). C12N 15/31 (2006.01) C12N 15/85 (2006.01) (74) Agents: TOO, Constance et al.; Gowling WLG (Canada) LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario K11 3 1C3 (CA). PCT/CA2017/050238 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 24 February 2017 (24.02.2017) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 2016 (08.03.2016) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, CO., LTD. [CN/CN]; TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, City, 30015 (TW). ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every Pele Choi-Sing [CA/CA]; Apt kind of regional protection available): ARIPO (BW, GH, Toronto, Ontario M4Y 2W4 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, No.306, Yuanpei St., Hsin- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Feng-Yee; 6F, No. 161- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, East Road, Neihu, Taipei City, [Continued on next page] : CHONG, Joseph Street, Leung-Kei; (TW). CHANG, Min-Chuan — — = = = B loo d g lu cose lev e l (mg /m L) w › - H • o o (0 (54) OF TOLL PNEUMOLYSIN PEPTIDES 111.8 -LIKE RECEPTOR AS 4 RELATED 342.83 ANTAGONISTS AGAINST DISEASES 132.1 TOLL-LIKE RECEPTOR 4 AND METHODS (57) : The present invention relates to isolated peptides from pneumolysin (PLY) and their use as antagonists of toll-like receptor 4 (TLR-4). Bind of said peptides results in de- creased activity of TLR-4. Particularly, the present invention provides isolated peptides from the C-terminal region of PLY which are effective in treatment of TLR-4 related activation condi- tions such as diabetes and atherosclerosis. = OF = = E _— = = — — 1-1 0 IN ei N kr) 1-1 IN 1-1 0 ei Non-DM STZ+ STZ+ control vehicle C7OPLY4 Fig. 3 O WO 2017/152270 Al 1#11101M011010112010EMOMOVINEDIDEOHOMOVOIMIE SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). with sequence listing part of description (Rule 5.2(a)) Published: — with international search report (Art. 21(3))
SG11201807729YA 2016-03-08 2017-02-24 Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases SG11201807729YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305164P 2016-03-08 2016-03-08
PCT/CA2017/050238 WO2017152270A1 (en) 2016-03-08 2017-02-24 Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases

Publications (1)

Publication Number Publication Date
SG11201807729YA true SG11201807729YA (en) 2018-10-30

Family

ID=59786223

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807729YA SG11201807729YA (en) 2016-03-08 2017-02-24 Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases

Country Status (9)

Country Link
US (2) US10287328B2 (en)
EP (1) EP3426677B1 (en)
KR (1) KR20180120738A (en)
CN (1) CN109071614B (en)
AU (1) AU2017231108B2 (en)
CA (1) CA3016815A1 (en)
SG (1) SG11201807729YA (en)
TW (1) TWI769150B (en)
WO (1) WO2017152270A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102213878B1 (en) * 2019-03-25 2021-02-05 충남대학교 산학협력단 Composition for prevention, improving or treatment of chronic pain comprising PAT4

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1993A (en) 1841-02-23 Elbridge G Matthews Manufacture of plows
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2555803A1 (en) * 2004-02-13 2005-08-27 Sanofi Pasteur Limited Pneumolysin derivatives
WO2015082501A1 (en) * 2013-12-03 2015-06-11 Virometix Ag Proline-rich peptides protective against s. pneumoniae

Also Published As

Publication number Publication date
WO2017152270A1 (en) 2017-09-14
AU2017231108A1 (en) 2018-09-27
CN109071614B (en) 2022-09-06
CA3016815A1 (en) 2017-09-14
AU2017231108B2 (en) 2021-06-17
US10287328B2 (en) 2019-05-14
EP3426677B1 (en) 2023-12-06
EP3426677A1 (en) 2019-01-16
US20170260241A1 (en) 2017-09-14
TWI769150B (en) 2022-07-01
EP3426677C0 (en) 2023-12-06
EP3426677A4 (en) 2019-11-20
US20190359658A1 (en) 2019-11-28
KR20180120738A (en) 2018-11-06
TW201739759A (en) 2017-11-16
CN109071614A (en) 2018-12-21

Similar Documents

Publication Publication Date Title
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201808797XA (en) T cell receptors
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201805001UA (en) Method of treating influenza a
SG11201805497QA (en) Mutated truncated von willebrand factor
SG11201905640XA (en) Oncogenic splice variant determination
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof